Embecta (NASDAQ:EMBC – Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.700-2.900 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on EMBC. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Wednesday, November 27th. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $13.00 to $20.00 in a research note on Monday, December 2nd.
Get Our Latest Stock Report on EMBC
Embecta Stock Performance
Embecta (NASDAQ:EMBC – Get Free Report) last posted its quarterly earnings data on Tuesday, November 26th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.05. The business had revenue of $286.10 million during the quarter, compared to analyst estimates of $276.97 million. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. The company’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.59 earnings per share. On average, research analysts predict that Embecta will post 2.84 earnings per share for the current year.
Embecta Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 6th were given a $0.15 dividend. The ex-dividend date was Friday, December 6th. This represents a $0.60 annualized dividend and a dividend yield of 3.30%. Embecta’s dividend payout ratio is presently 44.44%.
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
- Five stocks we like better than Embecta
- What Are Dividend Achievers? An Introduction
- Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead?
- CD Calculator: Certificate of Deposit Calculator
- RTX and Lockheed Martin: Buy 1 for Today and 1 for Tomorrow
- How to Use the MarketBeat Stock Screener
- 3 Must-Have ETFs Set to Dominate This Quarter
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.